Microenvironmental Effects of PDT Combined with Targeted Molecular Theraphy

PDT联合靶向分子治疗的微环境效应

基本信息

  • 批准号:
    8555154
  • 负责人:
  • 金额:
    $ 20.69万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-09-07 至 2014-01-31
  • 项目状态:
    已结题

项目摘要

Molecular targeting in the AKT signaling pathway demonstrates significant potential as a combined modality approach to enhancing therapeutic response to PDT. Improvements in outcome when using this approach will clearly include the effect of molecular targeting agents on tumor microenvironment. In theory, molecular targeting could favorably modify the pre-PDT tumor environment so as to enhance cytotoxicity during PDT; it could also augment post-PDT vascular effects and tumor destruction. Consequently, the timing of molecular therapy relative to PDT deserves careful consideration. The rational development of translatable protocols incorporating PDT and molecular targeting will necessarily evolve from this research. Methods to be employed include custom-designed technologies in which we are well-experienced. Quantitative image analysis of immunohistochemically-stained sections will be used to define therapy effects on tumor oxygenation, vascular structure, and related histology. Diffuse optical spectroscopy will be used to longitudinally monitor tumor physiological processes, such as oxygenation and blood flow, over the course of treatment. We hypothesize that targeted molecular therapy in the AKT signaling pathway will selectively modulate tumor microenvironment, augmenting PDT tumor response without increasing normal tissue toxicity. Investigations conducted in orthotopic and ectopic tumor models of lung and ovarian cancer will be directed toward the following three aims. SPECIFIC AIM 1. To quantify the microenvironmental and therapeutic consequences of VEGF, EGFR and/or AKT signal inhibition after PDT. SPECIFIC AIM 2. To evaluate combined modality protocols that incorporate pre-PDT use of targeted molecular therapy and/or oxygen augmentation during PDT in order to produce a more favorable PDT microenvironment. SPECIFIC AIM 3. To determine how VEGF, EGFR and/or AKT signal inhibition affect normal tissue toxicity to PDT.
AKT信号通路中的分子靶向作为一种增强PDT治疗反应的联合方式显示出巨大的潜力。当使用这种方法时,结果的改善将明确包括分子靶向药物对肿瘤微环境的影响。理论上,分子靶向可以很好地改变PDT前的肿瘤环境,从而增强PDT期间的细胞毒性;它还可以增强pdt后血管效应和肿瘤破坏。因此,分子治疗相对于PDT的时机值得仔细考虑。结合PDT和分子靶向的可翻译协议的合理发展将必然从这项研究中发展。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Theresa M Busch其他文献

Theresa M Busch的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Theresa M Busch', 18)}}的其他基金

Project 2: Mitigation of radiation toxicity in treatment of sarcoma with FLASH vs. Standard dose rates
项目 2:使用 FLASH 与标准剂量率治疗肉瘤时减轻放射毒性
  • 批准号:
    10333799
  • 财政年份:
    2022
  • 资助金额:
    $ 20.69万
  • 项目类别:
Project 2: Mitigation of radiation toxicity in treatment of sarcoma with FLASH vs. Standard dose rates
项目 2:使用 FLASH 与标准剂量率治疗肉瘤时减轻放射毒性
  • 批准号:
    10573285
  • 财政年份:
    2022
  • 资助金额:
    $ 20.69万
  • 项目类别:
Photodynamic therapy with prior inhibition of epidermal growth factor receptor to stimulate antitumor innate immune response
预先抑制表皮生长因子受体的光动力疗法可刺激抗肿瘤先天免疫反应
  • 批准号:
    10545179
  • 财政年份:
    2019
  • 资助金额:
    $ 20.69万
  • 项目类别:
Photodynamic therapy with prior inhibition of epidermal growth factor receptor to stimulate antitumor innate immune response
预先抑制表皮生长因子受体的光动力疗法可刺激抗肿瘤先天免疫反应
  • 批准号:
    10314030
  • 财政年份:
    2019
  • 资助金额:
    $ 20.69万
  • 项目类别:
Oxygen and photosensitizer levels in photodynamic therapy of head and neck tumors
头颈肿瘤光动力治疗中的氧气和光敏剂水平
  • 批准号:
    7788863
  • 财政年份:
    2009
  • 资助金额:
    $ 20.69万
  • 项目类别:
Oxygen and photosensitizer levels in photodynamic therapy of head and neck tumors
头颈肿瘤光动力治疗中的氧气和光敏剂水平
  • 批准号:
    8066749
  • 财政年份:
    2009
  • 资助金额:
    $ 20.69万
  • 项目类别:
Oxygen and photosensitizer levels in photodynamic therapy of head and neck tumors
头颈肿瘤光动力治疗中的氧气和光敏剂水平
  • 批准号:
    8544397
  • 财政年份:
    2009
  • 资助金额:
    $ 20.69万
  • 项目类别:
Oxygen and photosensitizer levels in photodynamic therapy of head and neck tumors
头颈肿瘤光动力治疗中的氧气和光敏剂水平
  • 批准号:
    8257172
  • 财政年份:
    2009
  • 资助金额:
    $ 20.69万
  • 项目类别:
Oxygen and photosensitizer levels in photodynamic therapy of head and neck tumors
头颈肿瘤光动力治疗中的氧气和光敏剂水平
  • 批准号:
    7649943
  • 财政年份:
    2009
  • 资助金额:
    $ 20.69万
  • 项目类别:
Effects of Photodynamic Therapy on Tumor Oxygenation
光动力疗法对肿瘤氧合的影响
  • 批准号:
    6874348
  • 财政年份:
    2001
  • 资助金额:
    $ 20.69万
  • 项目类别:

相似海外基金

Elucidating resistance to AKT inhibition in metastatic breast cancer
阐明转移性乳腺癌对 AKT 抑制的耐药性
  • 批准号:
    2440937
  • 财政年份:
    2020
  • 资助金额:
    $ 20.69万
  • 项目类别:
    Studentship
The Risk of Novel AKT Inhibition on Lethal Neuroendocrine Prostate Cancer Development
新型 AKT 抑制对致死性神经内分泌前列腺癌发展的风险
  • 批准号:
    350042
  • 财政年份:
    2015
  • 资助金额:
    $ 20.69万
  • 项目类别:
    Studentship Programs
Mechanistic studies of cancer cell adaptive response to PI3K/AKT inhibition
癌细胞对 PI3K/AKT 抑制的适应性反应的机制研究
  • 批准号:
    9272854
  • 财政年份:
    2015
  • 资助金额:
    $ 20.69万
  • 项目类别:
Targeting RAS signaling with CDK and AKT inhibition in pancreatic cancer
通过 CDK 和 AKT 抑制作用靶向胰腺癌中的 RAS 信号传导
  • 批准号:
    8581465
  • 财政年份:
    2013
  • 资助金额:
    $ 20.69万
  • 项目类别:
Targeting RAS signaling with CDK and AKT inhibition in pancreatic cancer
通过 CDK 和 AKT 抑制作用靶向胰腺癌中的 RAS 信号传导
  • 批准号:
    8692694
  • 财政年份:
    2013
  • 资助金额:
    $ 20.69万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了